Intravascular adenoviral agents in cancer patients: Lessons from clinical trials

Cancer Gene Therapy

Volumn 9, Issue 12, 2002, Pages 979-986

  Reid, Tony ^a   Warren, Robert ^b   Kirn, David ^c,d  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Kirn Oncology Consulting   (United States)

Author keywords

Adenovirus; Cancer; Clinical trial; Gene therapy; Oncolytic virus

Indexed keywords

CG 7870; INTERLEUKIN 10; INTERLEUKIN 6; M PROTEIN; ONCOLYTIC VIRUS; ONYX 015; ORNITHINE CARBAMOYLTRANSFERASE; PROTEIN P53; SCH 58500; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; VIRUS VACCINE;

ADENOVIRUS; ASTHENIA; CANCER THERAPY; CHILL; CLINICAL TRIAL; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME DEFICIENCY; FEVER; FLU LIKE SYNDROME; GENE EXPRESSION; GENE THERAPY; HEPATIC ARTERY; HEPATITIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER CIRCULATION; LYMPHOCYTOPENIA; MYALGIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; THROMBOCYTOPENIA; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; VIRUS REPLICATION; DRUG ADMINISTRATION ROUTE; GENE VECTOR; GENETICS; IMMUNOLOGY; MAXIMUM TOLERATED DOSE; METHODOLOGY; NEOPLASM; STATISTICS; TRANSGENE; VIROLOGY;

ADENOVIRIDAE; ONYX;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; MAXIMUM TOLERATED DOSE; NEOPLASMS; TRANSGENES; VIRAL VACCINES; VIRUS REPLICATION;

EID: 0036904741     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700539     Document Type: Review

References (52)

1. McCormick F. Cancer gene therapy: Fringe or cutting edge? Nat Rev Cancer. 2001;1:130-141.
2. Kozarsky KF, Wilson JM. Gene therapy: Adenovirus vectors. Curr Opin Genet Dev. 1993;3:499-503.
3. Roth J, Cristiano RJ. Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst. 1997;89: 21-39.
4. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med. 2001;7:781-787.
5. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274:373-376.
6. Heise C, Hermiston T, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective antitumoral efficacy. Nat Med. 2000;6:1134-1139.
7. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces antiglioma effect in vivo. Oncogene. 2000;19:2-12.
8. Hallenbeck PL, Chang YN, Hay C, et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther. 1999;10:1721-1733.
9. Yu D, Sakamoto G, Henderson DR. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 1999;59:1498-1504.
10. Yu D, Chen Y, Seng M, Dilley J, Henderson DR. The addition of adenovirus region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 1999;59:4200-4203.
11. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with Onyx-015, an E1B-55 kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res. 2000;60:6359-6366.
12. DeWeese T, Van der Poel H, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001;61:7464-7472.
13. Vasey P, Shulman L, Gore M, Kim D, Kaye S. Phase I trial of intraperitoneal Onyx - 015 adenovirus in patients with recurrent ovarian carcinoma. Proc Am Soc Clin Oncol. 2000;19:1512 (abstract).
14. Heise C, Williams A, Xue S, Propst M, Kim D. Intravenous administration of ONYX-015, a selectively-replicating adenovirus, induces antitumoral efficacy. Cancer Res. 1999;59: 2623-2628.
15. Marshall E. Clinical trials: Gene therapy death prompts review of adenovirus vector. Science. 1999;286:2244-2245.
16. Beardsley T. Gene therapy setback. Sci Am. 2000;282:36-37.
17. Jenks S. Gene therapy death - Everyone has to share in the guilt. J Natl Cancer Inst. 2000;92:98-100.
18. Miller H. Letter to the editor. Science. 2000;287:591.
19. Barker DD, Berk AJ. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology. 1987;156:107-121.
20. Bischoff JR, Kim DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53 -deficient human tumor cells [see comments]. Science. 1996;274:373-376.
21. Heise C, Sampson JA, Williams A, McCormick F, Von HD, Kim DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents [see comments]. Nat Med. 1997;3:639-645.
22. Harada J, Berk A. p53-independent and -dependent requirements for E1B-55 kD in adenovirus type 5 replication. J Virol. 1999;73:5333-5344.
23. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, zur Hausen H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol. 1998;72:9470-9478.
24. Goodrum FD, Omelles DA. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol. 1998;72:9479-9490.
25. Rogulski K, Freytag S, Zhang K, et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res. 2000;60:1193-1196.
26. Ries SJ, Brandts CH, Chung AS, et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med. 2000;6:1128-1133.
27. Kim D, Hermiston T, McCormick F. ONYX-015: Clinical data are encouraging. Nat Med. 1998;4:1341-1342.
28. Kim D, Nemunaitis J, Ganly I, et al. A phase II trial of intratumoral injection with an E1B-deleted adenovirus, ONYX-015, in patients with recurrent, refractory head and neck cancer. Proc Am Soc Clin Oncol. 1998;17:391a.
29. Khuri F, Nemunaitis J, Ganly I, et al. A controlled trial of Onyx-015, an E1B gene-deleted adenovirus, in combination with chemotherapy in patients with recurrent head and neck cancer. Nat Med. 2000;6:879-885.
30. Kim DH, Khuri F, Ganly I, et al. A phase II trial of ONYX- 015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Proc Am Soc Clin Oncol. 1999;18:1505.
31. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents [see comments]. Nat Med. 1997;3:639-645.
32. Reid A, Galanis E, Abbruzzese J, Romel L, Rubin J, Kim D. A phase I/II trial of ONYX-015 administered by hepatic artery infusion to patients with colorectal carcinoma. EORTC-NCI-AACR Meeting on Molecular Therapeutics of Cancer, 1999.
33. Wills KN, Maneval DC, Menzel P, et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther. 1994;5:1079-1088.
34. Mujoo K, Maneval D, Anderson S, Gutterman J. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene. 1996;12:1617-1623.
35. Nemunaitis J, Swisher SG, Timmons T, et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol. 2000;18:609-622.
36. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997;57:2559-2563.
37. Barker DD, Berk AJ. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology. 1987;156:107-121.
38. Reid T, Galanis E, Abbruzzese J, et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial. Gene Ther. 2001;8:1618-1626.
39. Reid T, Galanis E, Abbruzzese J, et al. Hepatic artery infusion of Onyx-015, a replication-selective adenovirus, in combination with 5-FU/leucovorin for gastrointestinal carcinoma metastatic to the liver: A phase I/II clinical trial. Proc Am Soc Clin Oncol. 2000;19:953 (abstract).
40. Nemunaitis J, Cunningham C, Buchanan A, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility and biological activity. Gene Ther. 2001;8:746-759.
41. Alexander HR, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol. 1998;16:1479-1489.
42. Brusilow S, Maestri N. Urea cycle disorders: Diagnosis, pathophysiology and therapy. Adv Pediatr. 1996;43:127-170.
43. Yu D, Chen Y, Dilley J, et al. Antitumor synergy of CN787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res. 2001;61:517-525.
44. Chalavi A, Todo T, Martuza R, Rabkin S. Replication-competent herpes simplex vector G207/cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia. 1999;1:162-169.
45. Norman K, Lee P. Reovirus as a novel oncolytic agent. J Clin Invest. 2000;105:1035-1038.
46. Pecora AL, Rizvi N, Cohen GI, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol. 2002;20:2251-2266.
47. Coffey M, Strong J, Forsyth P, Lee P. Reovirus therapy of tumors with activated ras pathway. Science. 1998;282:1332-1334.
48. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995;1:938-943.
49. Roelvink P, Mi G, Einfeld D, Kovesdi I, Wickham T. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science. 1999;286:1568-1571.
50. Suzuki K, Fueyo J, Krasnykh VPR, Curiel D, Alemany R. A replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res. 2001;7:120-126.
51. Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson A, Wold W. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol. 2000;74:6147-6155.
52. Hermiston T. Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer. J Clin Invest. 2000;105:1169-1172.